1
|
Qi X, Gao C, Yin C, Fan J, Wu X, Di G, Wang J, Guo C. Development of quercetin-loaded PVCL–PVA–PEG micelles and application in inhibiting tumor angiogenesis through the PI3K/Akt/VEGF pathway. Toxicol Appl Pharmacol 2022; 437:115889. [DOI: 10.1016/j.taap.2022.115889] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Revised: 01/14/2022] [Accepted: 01/15/2022] [Indexed: 12/20/2022]
|
2
|
Abstract
Betulinic acid (3β-Hydroxy-20(29)-lupaene-28-oic acid, BA) has excellent anti-cancer activity but poor solubility and low bioavailability. To improve the antitumor activity of BA, a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol (PVCL-PVA-PEG) graft copolymer (Soluplus) encapsulated BA micelle (Soluplus-BA) was fabricated. The Soluplus-BA micelles presented a mean size of 54.77 ± 1.26 nm and a polydispersity index (PDI) of 0.083. The MTT assay results showed that Soluplus-BA micelles increased the inhibitory effect of BA on MDA-MB-231 cells, mainly due to the enhanced accumulation of reactive oxygen species (ROS) and the destruction of mitochondrial membrane potential (MMP). Soluplus-BA micelles induced the DNA double-strand breaks (DSBs) as the γH2AX foci increased. Moreover, Soluplus-BA also inhibited the tube formation and migration of human umbilical vein endothelial cells (HUVECs), and inhibited the neovascularization of the chicken chorioallantoic membrane (CAM). This angiogenesis inhibitory effect may be accomplished by regulating the HIF-1/VEGF-FAK signaling pathway. The in vivo study confirmed the improved anti-tumor effect of Soluplus-BA and its inhibitory effect on angiogenesis, demonstrating the possibility of Soluplus-BA as an effective anti-breast cancer drug delivery system.
Collapse
Affiliation(s)
- Xueju Qi
- Department of Pharmacy, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China
| | - Cong Gao
- Affiliated Hospital of Shandong Academy of Medical Sciences, The Third Affiliated Hospital of Shandong First Medical University, Jinan, China
| | - Chuanjin Yin
- Department of Pharmacy, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China
| | - Junting Fan
- Department of Pharmaceutical Analysis, School of Pharmacy, Nanjing Medical University, Nanjing, China
| | - Xiaochen Wu
- Department of Pharmacy, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China
| | - Chuanlong Guo
- Department of Pharmacy, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, China
| |
Collapse
|
3
|
Lombardi VRM, Carrera I, Cacabelos R. In vitro and in vivo cytotoxic effect of AntiGan against tumor cells. Exp Ther Med 2017; 15:2547-2556. [PMID: 29467852 PMCID: PMC5792761 DOI: 10.3892/etm.2017.5681] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2017] [Accepted: 08/23/2017] [Indexed: 12/14/2022] Open
Abstract
Novel effective chemopreventive agents against cancer are required to improve current therapeutic rates. The aim of the present study was to investigate the anti-carcinogenesis effect of AntiGan, an extract obtained from the European conger eel, Conger conger, in vitro (human tumor cell lines) and in vivo (murine model of colitis) models. The potential apoptogenic activity after 24 h of incubation with 10, 25 and 50 µl/ml AntiGan was reported using growth inhibition and apoptosis activity assays. In vivo studies were performed in mice by inducing colitis with oral administration of 2% dextran sulphate sodium (DSS) for 5 weeks. Apoptosis was observed in HL-60, Hs 313.T, SW-480, Caco-2 and HT-29 cell lines. The highest level of growth inhibition was observed in Caco-2 (66, 75.8 and 88.1%), HT-29 (56, 73 and 87.6%) and SW-480 (38.5, 61.6, 78.6%) for AntiGan doses of 10, 25 and 50 µl/ml, respectively, compared to untreated cells, while the results of the expression of genes associated with apoptosis indicated a downregulation of B-cell lymphoma 2 (Bcl-2) in all cell lines studied. In vivo, morphopathological alterations in the colon were analyzed by immunohistochemical and staining methods. Tumoral markers, including β-catenin, cyclooxygenase 2 and Bcl-2 were expressed in cryptal cells of the dysplastic colonic mucosa, whereas the levels of interferon-γ expression were also increased when no treatment was applied. In the experimental murine model, the optimal concentration of AntiGan for an effective dose-response was 10% in diet. These results suggested that AntiGan displays a powerful anti-inflammatory effect in DSS-induced colitis, acting as a chemopreventive agent against colon carcinogenesis, most likely due to its apoptogenic peptides that contribute to the induction of apoptosis.
Collapse
Affiliation(s)
- Valter R M Lombardi
- Department of Health Biotechnology, EuroEspes Biotechnology, 15165 Corunna, Spain
| | - Iván Carrera
- Department of Health Biotechnology, EuroEspes Biotechnology, 15165 Corunna, Spain
| | - Ramón Cacabelos
- EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, 15165 Corunna, Spain
| |
Collapse
|
4
|
Abstract
This study was carried out to isolate chemical constituents from the lipid enriched fraction of Ganoderma lucidum extract and to evaluate their anti-proliferative effect on tumor cells and human umbilical vein endothelial cells (HUVECs). Ergosterol derivatives (1-14) were isolated and purified from the lipid enriched fraction of G. lucidum. Their chemical structures were established by spectroscopic analyses or by comparison of mass and NMR spectral data with those reported previously. Amongst, compound 1 was purified and identified as a new one. All the compounds were evaluated for their anti-proliferative effect on human tumor cells and HUVECs in vitro. Compounds 9-13 displayed inhibitory activity against two types of human tumor cells and HUVECs, which indicated that these four compounds had both anti-tumor and anti-angiogenesis activities. Compound 2 had significant selective inhibition against two tumor cell lines, while 3 exhibited selective inhibition against HUVECs. The structure-activity relationships for inhibiting human HepG2 cells were revealed by 3D-QASR. Ergosterol content in different parts of the raw material and products of G. lucidum was quantified. This study provides a basis for further development and utilization of ergosterol derivatives as natural nutraceuticals and functional food ingredients, or as source of new potential antitumor or anti-angiogenesis chemotherapy agent.
Collapse
Affiliation(s)
- Shaodan Chen
- Guangdong Institute of Microbiology, State Key Laboratory of Applied Microbiology Southern China, Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Open Laboratory of Applied Microbiology, Guangzhou, China
- Yuewei Edible Fungi Technology Co. Ltd., Guangzhou, China
| | - Tianqiao Yong
- Guangdong Institute of Microbiology, State Key Laboratory of Applied Microbiology Southern China, Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Open Laboratory of Applied Microbiology, Guangzhou, China
- Yuewei Edible Fungi Technology Co. Ltd., Guangzhou, China
| | - Yifang Zhang
- Guangdong Institute of Microbiology, State Key Laboratory of Applied Microbiology Southern China, Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Open Laboratory of Applied Microbiology, Guangzhou, China
- Yuewei Edible Fungi Technology Co. Ltd., Guangzhou, China
| | - Jiyan Su
- Guangdong Institute of Microbiology, State Key Laboratory of Applied Microbiology Southern China, Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Open Laboratory of Applied Microbiology, Guangzhou, China
- Yuewei Edible Fungi Technology Co. Ltd., Guangzhou, China
| | - Chunwei Jiao
- Yuewei Edible Fungi Technology Co. Ltd., Guangzhou, China
| | - Yizhen Xie
- Guangdong Institute of Microbiology, State Key Laboratory of Applied Microbiology Southern China, Guangdong Provincial Key Laboratory of Microbial Culture Collection and Application, Guangdong Open Laboratory of Applied Microbiology, Guangzhou, China
- Yuewei Edible Fungi Technology Co. Ltd., Guangzhou, China
| |
Collapse
|
5
|
Wang X, Fu X, Zhao S, Fu X, Zhang H, Shao L, Li G, Fan C. Antiangiogenic properties of caudatin in vitro and in vivo by suppression of VEGF‑VEGFR2‑AKT/FAK signal axis. Mol Med Rep 2017; 16:8937-8943. [PMID: 28990104 PMCID: PMC5779977 DOI: 10.3892/mmr.2017.7730] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2017] [Accepted: 09/27/2017] [Indexed: 12/19/2022] Open
Abstract
Tumor angiogenesis provides essential nutrients and oxygen to the tumor microenvironment, which is important in tumor growth, progression and metastasis. Inhibition of tumor angiogenesis represents one of the most promising strategies in tumor therapy. The authors previously demonstrated that caudatin, one species of C‑21 steroidal from Cynanchum auriculatum (C. auriculatum), effectively inhibits human glioma growth in vitro and in vivo through triggering cell cycle arrest and apoptosis. However, little information regarding the antiangiogenic properties of caudatin in human glioma is available. Based on the author's previous study, the antiangiogenic effect of caudatin against human glioma was explored, and the underlying mechanism was investigated. The results suggested that caudatin treatment significantly inhibited HUVEC human umbilical vein endothelial cell proliferation, blocked the HUVECs migration, invasion and capillary‑like tube formation by disturbing the vascular endothelial growth factor (VEGF)‑VEGFR2‑protein kinase B (AKT)/focal adhesion kinase (FAK) signal axis. Notably, caudatin treatment abolished the glioma cell growth by suppression of the in vivo angiogenesis, which involved FAK and AKT dephosphorylation and inhibition of VEGF expression. The findings validated the antiangiogenic potential of caudatin in hunting human glioma.
Collapse
Affiliation(s)
- Xinzhi Wang
- Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China
| | - Xiaoting Fu
- Key Lab of Cerebral Microcirculation in Universities of Shandong, Taishan Medical University, Taian, Shandong 271000, P.R. China
| | - Shijun Zhao
- Key Lab of Cerebral Microcirculation in Universities of Shandong, Taishan Medical University, Taian, Shandong 271000, P.R. China
| | - Xiaoyan Fu
- Key Lab of Cerebral Microcirculation in Universities of Shandong, Taishan Medical University, Taian, Shandong 271000, P.R. China
| | - Huifang Zhang
- Key Lab of Cerebral Microcirculation in Universities of Shandong, Taishan Medical University, Taian, Shandong 271000, P.R. China
| | - Lurong Shao
- Key Lab of Cerebral Microcirculation in Universities of Shandong, Taishan Medical University, Taian, Shandong 271000, P.R. China
| | - Gang Li
- Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China
| | - Cundong Fan
- Key Lab of Cerebral Microcirculation in Universities of Shandong, Taishan Medical University, Taian, Shandong 271000, P.R. China
| |
Collapse
|
6
|
Liang Y, Zhang Y, Wang G, Li Y, Huang W. Penduliflaworosin, a Diterpenoid from Croton crassifolius, Exerts Anti-Angiogenic Effect via VEGF Receptor-2 Signaling Pathway. Molecules 2017; 22:molecules22010126. [PMID: 28098802 PMCID: PMC6155893 DOI: 10.3390/molecules22010126] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2016] [Revised: 01/04/2017] [Accepted: 01/04/2017] [Indexed: 12/31/2022] Open
Abstract
Anti-angiogenesis targeting vascular endothelial growth factor receptor-2 (VEGFR-2) has been considered as an important strategy for cancer therapy. Penduliflaworosin is a diterpenoid isolated from the plant Croton crassifolius. Our previous study showed that this diterpenoid possesses strong anti-angiogenic activity by inhibiting vessel formation in zebrafish. This study was conducted to further investigate the anti-angiogenic activity and mechanism of penduliflaworosin. Results revealed that penduliflaworosin significantly inhibited VEGF-induced angiogenesis processes including proliferation, invasion, migration, and tube formation of human umbilical vein endothelial cells (HUVECs). Moreover, it notably inhibited VEGF-induced sprout formation of aortic rings and blocked VEGF-induced vessel formation in mice. Western blotting studies showed that penduliflaworosin inhibited phosphorylation of the VEGF receptor-2 and its downstream signaling mediators in HUVECs, suggesting that the anti-angiogenic activity was due to an interference with the VEGF/VEGF receptor-2 pathway. In addition, molecular docking simulation indicated that penduliflaworosin could form hydrogen bonds within the ATP-binding region of the VEGF receptor-2 kinase unit. Finally, cytotoxicity assay showed that penduliflaworosin possessed little toxicity toward both cancer and normal cells. Taken together, our findings demonstrate that penduliflaworosin exerts its anti-angiogenic effect via the VEGF receptor-2 signaling pathway. The anti-angiogenic property and low cytotoxicity of penduliflaworosin suggest that it may be useful in cancer treatments.
Collapse
Affiliation(s)
- Yeyin Liang
- Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, China.
| | - Yubo Zhang
- Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, China.
| | - Guocai Wang
- Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, China.
| | - Yaolan Li
- Institute of Traditional Chinese Medicine and Natural Products, College of Pharmacy, Jinan University, Guangzhou 510632, China.
| | - Weihuan Huang
- Key Laboratory of Regenerative Medicine, Ministry of Education, Jinan University, Guangzhou 510632, China.
- Department of Developmental & Regenerative Biology, Jinan University, Guangzhou 510632, China.
| |
Collapse
|
7
|
Desroches-Castan A, Quélard D, Demeunynck M, Constant JF, Dong C, Keramidas M, Coll JL, Barette C, Lafanechère L, Feige JJ. A new chemical inhibitor of angiogenesis and tumorigenesis that targets the VEGF signaling pathway upstream of Ras. Oncotarget 2016; 6:5382-411. [PMID: 25742784 PMCID: PMC4467156 DOI: 10.18632/oncotarget.2979] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Accepted: 12/19/2014] [Indexed: 02/07/2023] Open
Abstract
The efficacy of anti-angiogenic therapies on cancer patients is limited by the emergence of drug resistance, urging the search for second-generation drugs. In this study, we screened an academic chemical library (DCM, University of Grenoble-Alpes) and identified a leader molecule, COB223, that inhibits endothelial cell migration and proliferation. It inhibits also Lewis lung carcinoma (LLC/2) cell proliferation whereas it does not affect fibroblast proliferation. The anti-angiogenic activity of COB223 was confirmed using several in vitro and in vivo assays. In a mouse LLC/2 tumor model, ip administration of doses as low as 4 mg/kg COB223 efficiently reduced the tumor growth rate. We observed that COB223 inhibits endothelial cell ERK1/2 phosphorylation induced by VEGF, FGF-2 or serum and that it acts downstream of PKC and upstream of Ras. This molecule represents a novel anti-angiogenic and anti-tumorigenic agent with an original mechanism of action that deserves further development as an anti-cancer drug.
Collapse
Affiliation(s)
- Agnès Desroches-Castan
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1036, Biology of Cancer and Infection, Grenoble, F-38054, France.,Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France
| | - Delphine Quélard
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1036, Biology of Cancer and Infection, Grenoble, F-38054, France.,Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France.,Janssen, Pharmaceutical Companies of Johnson and Johnson, Issy-les-Moulineaux, F-92130, France
| | - Martine Demeunynck
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Centre National de la Recherche Scientifique (CNRS), UMR 5063, Department of Molecular Pharmacochemistry, Grenoble, F-38041, France
| | - Jean-François Constant
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Centre National de la Recherche Scientifique (CNRS), UMR 5250, Department of Molecular Chemistry, Grenoble, F-38041, France
| | - Chongling Dong
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Centre National de la Recherche Scientifique (CNRS), UMR 5250, Department of Molecular Chemistry, Grenoble, F-38041, France
| | - Michelle Keramidas
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 823, Albert Bonniot Research Center, La Tronche, F-38700, France
| | - Jean-Luc Coll
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 823, Albert Bonniot Research Center, La Tronche, F-38700, France
| | - Caroline Barette
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1038, Large Scale Biology, Grenoble, F-38054, France
| | - Laurence Lafanechère
- Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France.,Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 823, Albert Bonniot Research Center, La Tronche, F-38700, France
| | - Jean-Jacques Feige
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1036, Biology of Cancer and Infection, Grenoble, F-38054, France.,Univ. Grenoble-Alpes, Department of Chemistry, Biology and Health Sciences, Grenoble, F-38000, France.,Commissariat à l'Energie Atomique (CEA), DSV/iRTSV, Grenoble, F-38054, France
| |
Collapse
|
8
|
Pathania AS, Wani ZA, Guru SK, Kumar S, Bhushan S, Korkaya H, Seals DF, Kumar A, Mondhe DM, Ahmed Z, Chandan BK, Malik F. The anti-angiogenic and cytotoxic effects of the boswellic acid analog BA145 are potentiated by autophagy inhibitors. Mol Cancer 2015; 14:6. [PMID: 25608686 PMCID: PMC4509694 DOI: 10.1186/1476-4598-14-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2014] [Accepted: 12/16/2014] [Indexed: 12/17/2022] Open
Abstract
Background While angiogenesis inhibitors represent a viable cancer therapy, there is preclinical and clinical data to suggest that many tumors develop resistance to such treatments. Moreover, previous studies have revealed a complex association between autophagy and angiogenesis, and their collective influence on tumorigenesis. Autophagy has been implicated in cytoprotection and tumor promotion, and as such may represent an alternative way of targeting apoptosis-resistant cancer cells. This study explored the anti-cancer agent and boswellic acid analog BA145 as an inducer of autophagy and angiogenesis-mediated cytoprotection of tumor cells. Methods Flow cytometry, western blotting, and confocal microscopy were used to investigate the role of BA145 mediated autophagy. ELISA, microvessel sprouting, capillary structure formation, aortic ring and wound healing assays were performed to determine the relationship between BA145 triggered autophagy and angiogenesis. Flow cytometery, western blotting, and microscopy were employed to examine the mechanism of BA145 induced cell death and apoptosis. Live imaging and tumor volume analysis were carried out to evaluate the effect of BA145 triggered autophagy on mouse tumor xenografts. Results BA145 induced autophagy in PC-3 cancer cells and HUVECs significantly impeded its negative regulation on cell proliferation, migration, invasion and tube formation. These effects of BA145 induced autophagy were observed under both normoxic and hypoxic conditions. However, inhibition of autophagy using either pharmacological inhibitors or RNA interference enhanced the BA145 mediated death of these cells. Similar observations were noticed with sunitinib, the anti-angiogenic properties of which were significantly enhanced during combination treatments with autophagy inhibitors. In mouse tumor xenografts, co-treatment with chloroquinone and BA145 led to a considerable reduction in tumor burden and angiogenesis compared to BA145 alone. Conclusion These studies reveal the essential role of BA145 triggered autophagy in the regulation of angiogenesis and cytoprotection. It also suggests that the combination of the autophagy inhibitors with chemotherapy or anti-angiogenic agents may be an effective therapeutic approach against cancer. Electronic supplementary material The online version of this article (doi:10.1186/1476-4598-14-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Anup S Pathania
- Department of Cancer Pharmacology, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, Jammu and Kashmir, 180001, India. .,Academy of Scientific and Innovative Research (AcSIR), New Delhi, 110001, India.
| | - Zahoor A Wani
- Department of Cancer Pharmacology, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, Jammu and Kashmir, 180001, India.
| | - Santosh K Guru
- Department of Cancer Pharmacology, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, Jammu and Kashmir, 180001, India.
| | - Suresh Kumar
- Department of Cancer Pharmacology, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, Jammu and Kashmir, 180001, India. .,Academy of Scientific and Innovative Research (AcSIR), New Delhi, 110001, India.
| | - Shashi Bhushan
- Department of Cancer Pharmacology, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, Jammu and Kashmir, 180001, India.
| | - Hasan Korkaya
- Department of Biochemistry and Molecular Biology, Georgia Regents University Cancer Center, 1410 Laney Walker Boulevard CN2136, Augusta, GA, 30912, USA.
| | - Darren F Seals
- Department of Biology, Appalachian State University, 572 Rivers Street, Boone, NC, 28608, USA.
| | - Ajay Kumar
- Department of Cancer Pharmacology, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, Jammu and Kashmir, 180001, India.
| | - Dilip M Mondhe
- Department of Cancer Pharmacology, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, Jammu and Kashmir, 180001, India.
| | - Zabeer Ahmed
- Department of Inflammation Pharmacology, Indian Institute of Integrative Medicine, Canal Road, Jammu, Jammu and Kashmir, 180001, India.
| | - Bal K Chandan
- Department of Inflammation Pharmacology, Indian Institute of Integrative Medicine, Canal Road, Jammu, Jammu and Kashmir, 180001, India.
| | - Fayaz Malik
- Department of Cancer Pharmacology, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, Jammu and Kashmir, 180001, India. .,Academy of Scientific and Innovative Research (AcSIR), New Delhi, 110001, India.
| |
Collapse
|
9
|
Zha Y, Gan P, Liu Q, Tan J. Relationship between polymorphism of angiotensin-converting enzyme gene insertion/deletion and risk of hepatocellular carcinoma in a Chinese Dai population. J Renin Angiotensin Aldosterone Syst 2014; 16:695-9. [PMID: 25208933 DOI: 10.1177/1470320314539829] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2014] [Accepted: 05/15/2014] [Indexed: 12/23/2022] Open
Affiliation(s)
- Yong Zha
- Department of Abdominal Surgery, The Third Affiliated Hospital of Kunming Medical University China
| | - Ping Gan
- Department of Abdominal Surgery, The Third Affiliated Hospital of Kunming Medical University China
| | - Qin Liu
- Department of Abdominal Surgery, The Third Affiliated Hospital of Kunming Medical University China
| | - Jing Tan
- Department of Abdominal Surgery, The Third Affiliated Hospital of Kunming Medical University China
| |
Collapse
|
10
|
Calon A, Tauriello DVF, Batlle E. TGF-beta in CAF-mediated tumor growth and metastasis. Semin Cancer Biol 2014; 25:15-22. [PMID: 24412104 DOI: 10.1016/j.semcancer.2013.12.008] [Citation(s) in RCA: 239] [Impact Index Per Article: 23.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2013] [Revised: 12/19/2013] [Accepted: 12/30/2013] [Indexed: 12/14/2022]
Abstract
TGF-beta signaling is one of the major pathways controlling cell and tissue behavior not only in homeostasis but also in disease. During tumorigenesis TGF-beta orchestrated processes are key due to its dual role as tumor suppressor and tumor promoter. Important functions of this pathway have been described in a context-dependent manner both in epithelial cancer cells and in the tumor microenvironment during tumor progression. Carcinoma-associated fibroblasts (CAFs) are one of the most abundant stromal cell types in virtually all solid tumors. CAFs favor malignant progression by providing cancer cells with proliferative, migratory, survival and invasive capacities. A complex network of signaling pathways underlying their tumor-promoting properties is beginning to take shape. In this review, we examine current evidence on the emerging mechanisms involving TGF-beta in CAF-mediated cancer progression, and discuss their potential as therapeutic targets.
Collapse
Affiliation(s)
- A Calon
- Oncology Department, Institute for Research in Biomedicine, 08028 Barcelona, Spain.
| | - D V F Tauriello
- Oncology Department, Institute for Research in Biomedicine, 08028 Barcelona, Spain
| | - E Batlle
- Oncology Department, Institute for Research in Biomedicine, 08028 Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Spain.
| |
Collapse
|
11
|
Persigehl T, Ring J, Budny T, Hahnenkamp A, Stoeppeler S, Schwartz LH, Spiegel HU, Heindel W, Remmele S, Bremer C. Vessel Size Imaging (VSI) by Robust Magnetic Resonance (MR) Relaxometry: MR-VSI of Solid Tumors in Correlation with Immunohistology and Intravital Microscopy. Mol Imaging 2013. [DOI: 10.2310/7290.2013.00059] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Affiliation(s)
- Thorsten Persigehl
- From the Department of Radiology, University Hospital Cologne, Cologne, Germany; Department of Clinical Radiology, University Hospital Muenster, Muenster, Germany; Department of Radiology, Columbia University Medical Center, New York, NY; Department of General Surgery, Surgical Research, University Hospital Muenster, Muenster, Germany; Philips Research Europe, Hamburg, Germany; and Department of Radiology, St. Franziskus Hospital, Muenster, Germany
| | - Janine Ring
- From the Department of Radiology, University Hospital Cologne, Cologne, Germany; Department of Clinical Radiology, University Hospital Muenster, Muenster, Germany; Department of Radiology, Columbia University Medical Center, New York, NY; Department of General Surgery, Surgical Research, University Hospital Muenster, Muenster, Germany; Philips Research Europe, Hamburg, Germany; and Department of Radiology, St. Franziskus Hospital, Muenster, Germany
| | - Tymoteusz Budny
- From the Department of Radiology, University Hospital Cologne, Cologne, Germany; Department of Clinical Radiology, University Hospital Muenster, Muenster, Germany; Department of Radiology, Columbia University Medical Center, New York, NY; Department of General Surgery, Surgical Research, University Hospital Muenster, Muenster, Germany; Philips Research Europe, Hamburg, Germany; and Department of Radiology, St. Franziskus Hospital, Muenster, Germany
| | - Anke Hahnenkamp
- From the Department of Radiology, University Hospital Cologne, Cologne, Germany; Department of Clinical Radiology, University Hospital Muenster, Muenster, Germany; Department of Radiology, Columbia University Medical Center, New York, NY; Department of General Surgery, Surgical Research, University Hospital Muenster, Muenster, Germany; Philips Research Europe, Hamburg, Germany; and Department of Radiology, St. Franziskus Hospital, Muenster, Germany
| | - Sandra Stoeppeler
- From the Department of Radiology, University Hospital Cologne, Cologne, Germany; Department of Clinical Radiology, University Hospital Muenster, Muenster, Germany; Department of Radiology, Columbia University Medical Center, New York, NY; Department of General Surgery, Surgical Research, University Hospital Muenster, Muenster, Germany; Philips Research Europe, Hamburg, Germany; and Department of Radiology, St. Franziskus Hospital, Muenster, Germany
| | - Lawrence H. Schwartz
- From the Department of Radiology, University Hospital Cologne, Cologne, Germany; Department of Clinical Radiology, University Hospital Muenster, Muenster, Germany; Department of Radiology, Columbia University Medical Center, New York, NY; Department of General Surgery, Surgical Research, University Hospital Muenster, Muenster, Germany; Philips Research Europe, Hamburg, Germany; and Department of Radiology, St. Franziskus Hospital, Muenster, Germany
| | - Hans-Ullrich Spiegel
- From the Department of Radiology, University Hospital Cologne, Cologne, Germany; Department of Clinical Radiology, University Hospital Muenster, Muenster, Germany; Department of Radiology, Columbia University Medical Center, New York, NY; Department of General Surgery, Surgical Research, University Hospital Muenster, Muenster, Germany; Philips Research Europe, Hamburg, Germany; and Department of Radiology, St. Franziskus Hospital, Muenster, Germany
| | - Walter Heindel
- From the Department of Radiology, University Hospital Cologne, Cologne, Germany; Department of Clinical Radiology, University Hospital Muenster, Muenster, Germany; Department of Radiology, Columbia University Medical Center, New York, NY; Department of General Surgery, Surgical Research, University Hospital Muenster, Muenster, Germany; Philips Research Europe, Hamburg, Germany; and Department of Radiology, St. Franziskus Hospital, Muenster, Germany
| | - Stefanie Remmele
- From the Department of Radiology, University Hospital Cologne, Cologne, Germany; Department of Clinical Radiology, University Hospital Muenster, Muenster, Germany; Department of Radiology, Columbia University Medical Center, New York, NY; Department of General Surgery, Surgical Research, University Hospital Muenster, Muenster, Germany; Philips Research Europe, Hamburg, Germany; and Department of Radiology, St. Franziskus Hospital, Muenster, Germany
| | - Christoph Bremer
- From the Department of Radiology, University Hospital Cologne, Cologne, Germany; Department of Clinical Radiology, University Hospital Muenster, Muenster, Germany; Department of Radiology, Columbia University Medical Center, New York, NY; Department of General Surgery, Surgical Research, University Hospital Muenster, Muenster, Germany; Philips Research Europe, Hamburg, Germany; and Department of Radiology, St. Franziskus Hospital, Muenster, Germany
| |
Collapse
|
12
|
Stewart CJ, Abeysuriya D, Kumarasinghe P, Salfinger S, Tan J. Mullerian carcinosarcoma arising in the cecum associated with florid vascular proliferation/glomeruloid microvascular proliferation. Int J Gynecol Pathol 2013; 32:38-43. [PMID: 23202786 DOI: 10.1097/PGP.0b013e318257df2a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Angiogenesis is required for tumor growth, and the degree of new vessel formation correlates with adverse prognosis in many types of malignancies. It has now been appreciated that tumor-associated vasculature is heterogenous and sometimes includes a complex vasoformative process that has been termed florid vascular proliferation or glomeruloid microvascular proliferation. These vascular lesions are most characteristic of high-grade gliomas and neuroendocrine tumors but are being increasingly recognized in other types of neoplasias as well. Herein we report a case of carcinosarcoma arising within the cecal wall of a 62-yr-old patient that exhibited florid vascular proliferation, particularly at the time of peritoneal recurrence. Recognition of these tumor-associated vasoformative lesions may be important in view of their adverse prognostic association and may become therapeutically relevant considering the current developments in angiogenesis inhibitors.
Collapse
|
13
|
Altintas I, Heukers R, van der Meel R, Lacombe M, Amidi M, van Bergen En Henegouwen PM, Hennink WE, Schiffelers RM, Kok RJ. Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. J Control Release 2013; 165:110-8. [PMID: 23159529 DOI: 10.1016/j.jconrel.2012.11.007] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2012] [Revised: 11/05/2012] [Accepted: 11/10/2012] [Indexed: 11/21/2022]
Abstract
A novel, EGFR-targeted nanomedicine has been developed in the current study. Glutaraldehyde crosslinked albumin nanoparticles with a size of approximately 100nm were loaded with the multikinase inhibitor 17864-L(x)-a platinum-bound sunitinib analogue-which couples the drug to methionine residues of albumin and is released in a reductive environment. Albumin nanoparticles were surface-coated with bifunctional polyethylene glycol 3500 (PEG) and a nanobody-the single variable domain of an antibody-(Ega1) against the epidermal growth factor receptor (EGFR). EGa1-PEG functionalized nanoparticles showed a 40-fold higher binding to EGFR-positive 14C squamous head and neck cancer cells in comparison to PEGylated nanoparticles. 17864-L(x) loaded EGa1-PEG nanoparticles were internalized by clathrin-mediated endocytosis and ultimately digested in lysosomes. The intracellular routing of EGa1 targeted nanoparticles leads to a successful release of the kinase inhibitor in the cell and inhibition of proliferation whereas the non-targeted formulations had no antiproliferative effects on 14C cells. The drug loaded targeted nanoparticles were as effective as the free drug in vitro. These results demonstrate that multikinase inhibitor loaded nanoparticles are interesting nanomedicines for the treatment of EGFR-positive cancers.
Collapse
|
14
|
Huang B, Liu B, Yang L, Li Y, Cheng M, Huang D, Wang H, Zhang X, Zheng J, Li Q, Ji W, Zhou Y, Lu J. Functional genetic variants of c-Jun and their interaction with smoking and drinking increase the susceptibility to lung cancer in southern and eastern Chinese. Int J Cancer 2012; 131:E744-58. [DOI: 10.1002/ijc.27407] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2011] [Accepted: 11/24/2011] [Indexed: 01/30/2023]
|
15
|
Li M, Wu S, Liu Z, Zhang W, Xu J, Wang Y, Liu J, Zhang D, Tian H, Li Y, Ye W. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway. Biochem Pharmacol 2012; 83:1251-60. [PMID: 22305746 DOI: 10.1016/j.bcp.2012.01.023] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2011] [Revised: 01/09/2012] [Accepted: 01/17/2012] [Indexed: 11/28/2022]
Abstract
Angiogenesis is crucial for carcinogenesis and other angiogenic processes. Arenobufagin, one of the major components of toad venom, is a traditional Chinese medicine used for cancer therapy. It inhibits cell growth in several cancer cell lines. However, little is known about arenobufagin's anti-angiogenic activity. In this study, we showed that arenobufagin inhibited vascular endothelial growth factor (VEGF)-induced viability, migration, invasion and tube formation in human umbilical vein endothelial cells (HUVECs) in vitro. Arenobufagin also suppressed sprouting formation from VEGF-treated aortic rings in an ex vivo model. Furthermore, we found that arenobufagin blocked angiogenesis in a matrigel plugs assay. Computer simulations suggested that arenobufagin interacted with the ATP-binding sites of VEGFR-2 by docking. In addition, arenobufagin inhibited VEGF-induced VEGFR-2 auto-phosphorylation and suppressed the activity of VEGFR-2-mediated signaling cascades. Taken together, our findings demonstrate that arenobufagin is a specific inhibitor of VEGF-mediated angiogenesis.
Collapse
Affiliation(s)
- Manmei Li
- Institute of Traditional Chinese Medicine and Natural Products, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Jinan University, Guangzhou, PR China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Ferrando M, Gueron G, Elguero B, Giudice J, Salles A, Leskow FC, Jares-Erijman EA, Colombo L, Meiss R, Navone N, De Siervi A, Vazquez E. Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer. Angiogenesis 2011; 14:467-79. [PMID: 21833623 DOI: 10.1007/s10456-011-9230-4] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2011] [Accepted: 07/30/2011] [Indexed: 10/17/2022]
Abstract
Prostate cancer (PCa) is the second leading cause of cancer-associated death in men. Once a tumor is established it may attain further characteristics via mutations or hypoxia, which stimulate new blood vessels. Angiogenesis is a hallmark in the pathogenesis of cancer and inflammatory diseases that may predispose to cancer. Heme oxygenase-1 (HO-1) counteracts oxidative and inflammatory damage and was previously reported to play a key role in prostate carcinogenesis. To gain insight into the anti-tumoral properties of HO-1, we investigated its capability to modulate PCa associated-angiogenesis. In the present study, we identified in PC3 cells a set of inflammatory and pro-angiogenic genes down-regulated in response to HO-1 overexpression, in particular VEGFA, VEGFC, HIF1α and α5β1 integrin. Our results indicated that HO-1 counteracts oxidative imbalance reducing ROS levels. An in vivo angiogenic assay showed that intradermal inoculation of PC3 cells stable transfected with HO-1 (PC3HO-1) generated tumours less vascularised than controls, with decreased microvessel density and reduced CD34 and MMP9 positive staining. Interestingly, longer term grown PC3HO-1 xenografts displayed reduced neovascularization with the subsequent down-regulation of VEGFR2 expression. Additionally, HO-1 repressed nuclear factor κB (NF-κB)-mediated transcription from an NF-κB responsive luciferase reporter construct, which strongly suggests that HO-1 may regulate angiogenesis through this pathway. Taken together, these data supports a key role of HO-1 as a modulator of the angiogenic switch in prostate carcinogenesis ascertaining it as a logical target for intervention therapy.
Collapse
|